Analyst: Lundbeck drug could be a heavyweight
Lundbeck’s newly-approved schizophrenia drug Abilify Maintena could prove a heavyweight within a growing market segment, says an analyst, and the timing is great when it comes to the drug's chances for success overseas.
by Stefan Singh Kailay
Last week’s FDA approval of the schizophrenia drug Abilify Maintena could earn Lundbeck billions, assesses Sydbank analyst Søren Løntoft Hansen.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Schizofrenia drug from Lundbeck approved by the FDA
For abonnenter
Lundbeck wins European approval for alcohol pill
For abonnenter
